PHARMACOVIGILANCE: WHEN ADVERSE DRUG EVENTS OCCUR. Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz, Pharm.D., FISMP
|
|
- Paul Welch
- 5 years ago
- Views:
Transcription
1 PHARMACOVIGILANCE: WHEN ADVERSE DRUG EVENTS OCCUR Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz, Pharm.D., FISMP
2 Disclosure Information PHARMACOVIGILANCE Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz, Pharm.D., FISMP I have no financial relationship to disclose. AND I will not discuss off label use and/or investigational use in my presentation. - List References here
3 Objectives Describe the difference between adverse drug reactions and medication errors Describe the role of pharmacovigilance in detection and prevention of adverse drug reactions Demonstrate how to classify and assess adverse drug reactions Use the elements of an effective medication event reporting system to increase reporting
4 WHAT ARE ADVERSE DRUG EVENTS? Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment 1 This includes: - Adverse Drug Reactions - Medication Errors - Allergic Reactions - Overdoses 1. World Health Organization (WHO). WHO Draft Guidelines for Adverse Event Reporting and Learning Systems. Geneva: WHO, 2005.
5 WHAT ARE ADVERSE DRUG EVENTS? ADVERSE DRUG REACTION (ADR) A response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for the medication of physiologic function. MEDICATION ERROR Any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer 1. World Health Organization (WHO). WHO Draft Guidelines for Adverse Event Reporting and Learning Systems. Geneva: WHO, 2005.
6 ADVERSE DRUG REACTIONS Bartlomiej Piechowski-Jozwiak, MD
7 WHAT IS PHARMACOVIGILANCE? The science and activities relating to the detections, assessment, understanding and prevention of adverse effects or any other drugrelated problem - World Health Organization 1.
8 WHY IS PHARMACOVIGILANCE NEEDED?
9 CLASSIC EXAMPLES OF SERIOUS ADRs MEDICATION Statins Thalidomide istotretinoin Aminophenazone (amidopyrine) Chloramphenicol Clioquinol Erythromycin estolate Fluothane Methyldopa Oral contraceptives Practolol Reserpine ADVERSE DRUG REACTION Rhabdomyolysis Congenital malformations Congenital malformations Agranulocytosis Aplastic anemia Myelooptic neuropathy (SMON) Cholestatic hepatitis Hepatocellular hepatitis Haemolytic anaemia Thromboembolism Sclerosing peritonitis Depression
10 OBJECTIVES OF PHARMACOVIGILANCE PROGRAMS Improvement of patient care and safety Improvement of public health and safety Contribution to the assessment of benefit, harm, effectiveness and risk of medicines Promotion of: - Education and clinical training - Effective communication to the public - Rational and safe use of medicines
11 HOW POST-MARKETING REPORTS GET TO FDA EVENT REPORT SYSTEM (FAERS) Contribution to the 5% Consumers Patients Healthcare Prof. FAERS* Database Regulatory Requirement 85% Manufacturer
12 HOW POST-MARKETING REPORTS GET TO FDA EVENT REPORT SYSTEM (FAERS) Safety Alerts Based on FAERS
13 PHARMACOVIGILANCE REPORTING Spontaneous reporting - Most common form of reporting - Performed by healthcare professionals/drug manufacturers Other methods of collecting safety data National pharmacovigilance centers WHO Program for International Drug Monitoring
14 WHO Program for International Drug Monitoring Established in response to the thalidomide disaster Approximately 10,000 babies were born with deformities Started out as 10 countries Became WHO Collaborating Center for International Drug Monitoring Named Uppsala Monitoring Center Includes 131 countries as of September Uppsala Monitoring Centre
15 Uppsala Monitoring Centre An Independent, self-funded, non-profit organization Largest global database of Individual Case Safety Reports (VigiBase TM ) on behalf of WHO Technical support and guidance to national centres in PV practice Support for countries with reporting and data management VigiFlow, a web-based system integrating international standards to record and manage ICSRs Training sessions, publications of scientific data 1. Uppsala Monitoring Centre
16 VigiBase TM Flow of Information Reporters PV Center VigiBase Manufacturer Communication Analysis
17 TIPS FOR IDENTIFICATION OF ADRs BY HEALTHCARE PROFESSIONALS New or worsening symptoms Atypical lab or diagnostic procedures ordered Abrupt, unexpected discontinuation of a drug or a substantial dosage increase or reduction New orders for antidotes: - Naloxone - Flumazenil - Diphenhydramine - Antiemetics - Vitamin K - Sodium polystyrene sulfonate - Corticosteroids - Antidiarrheals
18 CLASSIFICATION OF ADRs
19 CLASSIFICATION OF ADRs
20 NARANJO ADR PROBABILITY SCALE
21 LIVERPOOL ADR CAUSALITY TOOL
22 SIGNALS A signal is a set of data constituting reported information on a possible, not previously known/documented, causal relationship because an adverse event and a drug 1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:
23 SIGNAL DEFINITION
24 VigiBase TM Flow of Information
25 DETERMINING SIGNAL PROBABILITY (PROPORTIONAL REPORTING RATIO) 1. Evans SJ et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf Oct-Nov;10(6):483-6.
26 PROPORTIONAL REPORTING RATIO (RIFBUTIN AND UVEITIS) 1. Evans SJ et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf Oct-Nov;10(6):483-6.
27 PROPORTIONAL REPORTING RATIO (RIFBUTIN AND UVEITIS) 1. Evans SJ et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf Oct-Nov;10(6):483-6.
28 REPORTING ADVERSE EVENTS Premarketing Trials Postmarketing surveillance Ministry/Departments of Health Pharmacovigilance Centers FDA Adverse Event Reporting System Institute for Safe Medication Practices MEDMARX Published Reports Uppsala Monitoring Center
29 Assessment Question 1 A 76-year-old patient is prescribed intravenous vancomycin 1500 mg every 12 hours on August 10. e patient s SCr on the morning of August 10 is 2.3 mg/dl, peaking at 5.4 mg/dl on August 15. Trough vancomycin level is 24.6 mcg/ml on August 16. Renal sonography is normal, and serum electrolytes are normal. According to the Naranjo algorithm, which one of the following ratings is most appropriate for the possible ADR of vancomycin and acute kidney injury in this patient? A. Highly Probably B. Probably C. Possible D. Doubtful
30
31 Assessment Question 2 N.P. is a 54-year-old man with superior vena cava stenosis, end-stage kidney disease, severe pruritus, and asthma. He is taken to the radiology suite for an angioplasty procedure. e patient is administered intravenous fentanyl 200 mcg, midazolam 4 mg, and morphine 10 mg. N.P. tolerates the procedure well, but in the recovery area, he has acute anxiety and tachypnea, with oxygen saturation levels decreasing to 89% 92%. Two doses each of flumazenil 0.5 mg and naloxone 0.4 mg are administered, and his oxygen saturation increases to 93% 95% The nurse circulator on N.P. s unit calls the pharmacotherapy specialist and asks whether an ADR report should be completed. Which one of the following is the best response to this question? A. Circulating nurse does not need to complete an ADR form because the reaction to fentanyl is expected. B. Patient s end-stage kidney disease should have limited the dosages of sedation agents, so an ADR form should be completed. C. Use of naloxone in 0.4-mg doses is dangerous, and an ADR report should be completed to enforce education on the use of reversal agents. D. No significant clinical harm occurred, so an ADR form should not be completed.
32 Assessment Question 2 N.P. is a 54-year-old man with superior vena cava stenosis, end-stage kidney disease, severe pruritus, and asthma. He is taken to the radiology suite for an angioplasty procedure. e patient is administered intravenous fentanyl 200 mcg, midazolam 4 mg, and morphine 10 mg. N.P. tolerates the procedure well, but in the recovery area, he has acute anxiety and tachypnea, with oxygen saturation levels decreasing to 89% 92%. Two doses each of flumazenil 0.5 mg and naloxone 0.4 mg are administered, and his oxygen saturation increases to 93% 95% The nurse circulator on N.P. s unit calls the pharmacotherapy specialist and asks whether an ADR report should be completed. Which one of the following is the best response to this question? A. Circulating nurse does not need to complete an ADR form because the reaction to fentanyl is expected. B. Patient s end-stage kidney disease should have limited the dosages of sedation agents, so an ADR form should be completed. C. Use of naloxone in 0.4-mg doses is dangerous, and an ADR report should be completed to enforce education on the use of reversal agents. D. No significant clinical harm occurred, so an ADR form should not be completed.
33 MEDICATION ERRORS Rabih Dabliz, Pharm.D., FISMP
34 Do You Have a Safety Culture in Your Organization?
35
36 Polling Question 1 Hospitals A and B are two 300-bed academic hospitals located within 200 meters of each other and offering similar clinical services to the community. During their monthly quality meeting, Hospital A reports 50 medication events while Hospital B reports 250. In which hospital do you feel safer? A. Hospital A B. Hospital B
37 Polling Question 1 Hospitals A and B are two 300-bed academic hospitals located within 200 meters of each other and offering similar clinical services to the community. During their monthly quality meeting, Hospital A reports 50 medication events while Hospital B reports 250. In which hospital do you feel safer? A. Hospital A B. Hospital B
38 EVENT REPORTING REPORTED
39 EVENT REPORTING REPORTED ACTUAL
40 What are the Barriers to Reporting in Your Organization?
41 DETECTING MEDICATION ERRORS
42 1. INCIDENT REPORT REVIEW Most frequently used in healthcare facilities Based on voluntary reporting Can be done by: - Paper - Telephone - - Electronic Under-reporting is a major drawback
43 1. INCIDENT REPORT REVIEW The Reporter needs to only answer 3 questions: 1. What happened? 2. Why do you think it happened? 3. How can it be prevented?
44 2. PATIENT CHART REVIEW Concurrent or retrospective medical record review Conducted by trained healthcare providers Helps detect prescribing and monitoring incidents
45 3. DIRECT OBSERVATION Observes medication administration at the bedside Helps identify administration and dispensing errors Not useful for prescribing/monitoring errors Optimize the audit process by developing a standardized audit tool that can be easily utilized by different members of the team
46 3. DIRECT OBSERVATION (SAMPLE AUDIT TOOL)
47
48 4. PHARMACIST INTERVENTIONS Helps identify prescribing errors and therapy optimization by tracking the various types of interventions performed by Pharmacist: - IV to PO - Renal/hepatic adjustment - Drug monitoring - Clinical Interventions - Medication Reconciliation
49 4. PHARMACIST INTERVENTIONS # Interventions per Month # & Type of Intervention per Pharmacist
50 5. TRIGGER TOOLS Helps identify potential adverse events using different triggers via detection of: 1. Certain Antidotes 2. Results from Laboratory Tests 3. Clinical Events
51 5. TRIGGER TOOLS Patient List Includes a column which flags patients who received an Antidote in Last 72 hours
52 5. TRIGGER TOOLS Once patient is identified, a customized report in the chart lists the antidote that was administered including: Date Time Dose Date & Time Antidote name & Dose Given
53 What to Do With the Data?
54 USING THE DATA Monthly or Quarterly Medication Safety/Quality Committees Dashboards Direct Feedback to Reporter Newsletters
55 REPORTING DASHBOARD
56 Additional Literature/References World Health Organization (WHO). WHO Draft Guidelines for Adverse Event Reporting and Learning Systems. Geneva: WHO, World Health Organization. Pharmacovigilance. World Health Organization (WHO). Fast Facts on Pharmacovigilance. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356: Evans SJ et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf Oct- Nov;10(6):483-6.
Pharmacovigilance. Dr. Anjan Adhikari Associate Professor Department of Pharmacology R G Kar Medical College & Hospital Kolkata
Pharmacovigilance Dr. Anjan Adhikari Associate Professor Department of Pharmacology R G Kar Medical College & Hospital Kolkata Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable.
More informationThe Importance of Reporting Adverse Drug Reactions and Creating a Culture of Safety. Kristy Malacos Magruder Hospital Pharmacy Systems, Inc.
The Importance of Reporting Adverse Drug Reactions and Creating a Culture of Safety Kristy Malacos Magruder Hospital Pharmacy Systems, Inc. Objectives Describe Adverse Drug Reactions (ADR)and the importance
More informationCLINICAL DECISION SUPPORT FOR ME/ADE PREVENTION
CLINICAL DECISION SUPPORT FOR ME/ADE PREVENTION Sandra Kane-Gill, PharmD, MSc, FCCP, FCCM Associate Professor of Pharmacy, Critical Care Medicine and the Clinical Translational Science Institute, University
More informationTITLE: SAFE USE OF MEDICINES IN ZANZIBAR A
Table of content Acknowledgements Introduction TITLE: SAFE USE OF MEDICINES IN ZANZIBAR A guide for health professionals in detecting and reporting adverse drug reaction. (Beautiful photograph tablets
More informationCLINICAL ANALYSIS OF ADVERSE DRUG REACTIONS. Christine Chamberlain, Pharm.D., BCPS, CDE FDA, CDER, OSE, Division of Pharmacovigilance
CLINICAL ANALYSIS OF ADVERSE DRUG REACTIONS Christine Chamberlain, Pharm.D., BCPS, CDE FDA, CDER, OSE, Division of Pharmacovigilance February 2015 2 Disclaimer The views in this presentation on clinical
More informationHigh-Alert Medications: A Look at the Safe Use of Narcotics. Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP)
High-Alert Medications: A Look at the Safe Use of Narcotics Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP) Risk Identification in Healthcare The detection of a potential or actual
More informationPatient Harm with Opioids: Can We Truly Reduce the Risk? Ali-Reza Shah-Mohammadi, PharmD, MS, FISMP
Patient Harm with Opioids: Can We Truly Reduce the Risk? Ali-Reza Shah-Mohammadi, PharmD, MS, FISMP Clinical Pharmacy Specialist Medication Safety Pharmacy Medication Management & Analytics The University
More informationExisting WHO work on Medicines Safety & Safe Use. Department of Essential Medicines and Health Products World Health Organization
Existing WHO work on Medicines Safety & Safe Use Department of Essential Medicines and Health Products World Health Organization WHO Pharmacovigilance & Medicines Safety Programme How it started Thalidomide
More informationKey Elements in Adverse Drug Interaction Safety Signals
Drug Saf (2013) 36:63 70 DOI 10.1007/s40264-012-0003-9 ORIGINAL RESEARCH ARTICLE Key Elements in Adverse Drug Interaction Safety Signals An Assessment of Individual Case Safety Reports Johanna Strandell
More informationAdverse Events Monitoring (aka Pharmacovigilance)
Adverse Events Monitoring (aka Pharmacovigilance) Presentation to American Conference Institute s FDA Boot Camp William W. Vodra May 16, 2007 Agenda What is pharmacovigilance (PV)? How does PV use adverse
More informationThe views in this presentation on clinical analysis of adverse drug reactions are my own opinion and do not necessarily represent the views of the
Clinical Analysis of Adverse Drug Reactions Christine Chamberlain, Pharm.D., BCPS Clinical Center Pharmacy Department National Institutes of Health February 2015 Disclaimer The views in this presentation
More informationPrinciples of Signal Detection. Pia Caduff-Janosa MD Annual Course May 2013
Principles of Signal Detection Pia Caduff-Janosa MD Annual Course May 2013 Outline What is a signal? Signal sources Triggers Assessment of potential risk Signal evaluation Outcome 2 Pia Caduff-Janosa,
More informationWho are we? Adverse Drug Reactions Applying Theory to Clinical Practice. WS SIG-MI Barcelona October
Adverse Drug Reactions Applying Theory to Clinical Practice Stephane Steurbaut, Brussels - Belgium Yolande Hanssens, Doha - Qatar ESCP Barcelona 30 October 2012 Who are we? yhanssens@hmc.org.qa y_hanssens@hotmail.com
More informationPractical Medicines Management
Practical Medicines Management Linda Bryant/Fiona Corbin/Leanne Te Karu Pharmac Seminar Series Medicines in Healthcare August 2015 Even people who have access to drugs may not receive the right medicine
More informationAdverse Experience Reporting
Managing and reporting adverse events Key learning objectives By the end of this session, you will be able to: Define and classify an adverse event; Differentiate between serious and severe adverse events;
More informationCare of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.
Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients
More informationMedication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski
Medication errors Impact of medication error guidance and regulation on drug-device combination products June 2017 Dan Wozinski Agenda Understand the management of medication errors within global requirements
More informationAdverse Drug Reactions Year 2 Clinical Pharmacology
1 Adverse Drug Reactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2018 2 Objectives Explain how to predict, identify and characterise an adverse
More informationAssessing the Performance Characteristics of Signals Used by a Clinical Event Monitor to Detect Adverse Drug Reactions in the Nursing Home
Assessing the Performance Characteristics of Signals Used by a Clinical Event Monitor to Detect Adverse Drug Reactions in the Nursing Home Steven M. Handler, MD, MS, 1,2 Joseph T. Hanlon, PharmD, MS 1,3-5
More information2/9/2016. A Multi-Disciplinary Program to Decrease the Rate of Preventable Harm from Medication Events. Objectives:
A Multi-Disciplinary Program to Decrease the Rate of Preventable Harm from Medication Events Michigan Pharmacist Association February 28, 2016 Steven Johnson, Pharm.D. Regional Clinical Director Gay Alcenius,
More informationPHARMACOVIGILANCE GLOSSARY
PHARMACOVIGILANCE GLOSSARY Section 1 Section 2 Section 3 Section 4 Definitions of terminology used for side effects Definitions of drug safety terms Definitions of risk terminology Definitions of general
More informationSetting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time?
Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time? Lewis S. Nelson, MD New York University School of Medicine New York City Poison Control Center Opioid Abuse Liability
More informationSafety Assessment in Clinical Trials and Beyond
Safety Assessment in Clinical Trials and Beyond Yuliya Yasinskaya, MD Medical Team Leader Division of Anti-Infective Products Center for Drug Evaluation and Research FDA Clinical Investigator Training
More informationApril 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director
More informationWELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Adverse Events in Clinical Trials: Definitions and Documentation May 2016 Objectives Recognize the
More informationBasic Principles in Pharmacology
L. 1 Dr. Mohammed AL-Zobaidy Basic Principles in Pharmacology Learning objectives: by the end of this lecture you should Understand the possible uses of drugs. Explain why a drug has different names. Identify
More informationClinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics Updated on 23 Feb 2017 I) OBJECTIVES 1. To provide a broad training and in-depth experience at a level sufficient for trainees to acquire competence and professionalism
More informationDisclosure. Screening for adverse drug events: a tool to improve safe medication use
Screening for adverse drug events: a tool to improve safe medication use John T. Holmes, PharmD, BCPS Assistant Professor Departments of Family Medicine and Pharmacy Practice Idaho State University Disclosure
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early recognition of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More informationRoutine signal detection and statistical tools on paediatrics
Routine signal detection and statistical tools on paediatrics Paediatric workshop 28 April 2014 Presented by: Cosimo Zaccaria Signal Management Pharmacovigilance Department An agency of the European Union
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More informationFaculty. Disclosures. Prescribing. A Multidisciplinary Approach to Preventing Medication Errors Associated with Insulin Therapy. Learning Objectives
A Multidisciplinary Approach to Preventing Medication Errors Associated with Insulin Therapy Faculty Matthew Grissinger, RPh, FISMP, FASCP Director, Error Reporting Programs Institute for Safe Medication
More informationCDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
More informationTestimony for the record. On behalf of the American Academy of Pediatrics. Before the Energy and Commerce Committee Health Subcommittee
Testimony for the record On behalf of the American Academy of Pediatrics Before the Energy and Commerce Committee Health Subcommittee American Academy of Pediatrics Department of Federal Affairs 601 13th
More informationDavid Dosa MD, MPH Assistant Professor of Medicine and Community Health The Warren Alpert School of Medicine, Brown University Director, Primary Care
David Dosa MD, MPH Assistant Professor of Medicine and Community Health The Warren Alpert School of Medicine, Brown University Director, Primary Care Geriatrics Clinic- Providence VAMC VA Grand Rounds
More informationLee B. Murdaugh, RPh, PhD
P T Chapter 40 Adverse Drug Reaction Reporting Lee B. Murdaugh, RPh, PhD LEARNING OBJECTIVES Define an adverse drug reaction. Discuss the detection of adverse drug reactions. Discuss the assessment of
More information6/6/2017. First Do No Harm SECTION 1 THE OPIOID CRISIS. Implementing an Opioid Stewardship Program in a HealthCare System OBJECTIVES
First Do No Harm Implementing an Opioid Stewardship Program in a HealthCare System Phil Chang, MD Kristy Deep, MD Doug Oyler, PharmD June 12, 2017 OBJECTIVES Explain the role of opioid stewardship as a
More information5. Current Activities
5. Current Activities 5. Current Activities The following discussion suggests only some of the kinds of activities and resources that can contribute to postmarketing surveillance. The Food and Drug Administration
More informationAllergy Status Identification And Documentation
Allergy Status Identification And Documentation Basic Medication Safety (BMS) Certification Course King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs Learning
More informationSPAGG. Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation
SPAGG Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation This sheet is to accompany all documentation agreed by SPAGG. This will assist maintenance of the guidelines as
More informationFDA s Response to the Opioid Crisis and the FDA Safe Use Initiative
FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.
More informationTABLE OF CONTENTS Risk of myocardial infarction with antiretroviral use 1-2
TABLE OF CONTENTS Risk of myocardial infarction with antiretroviral use 1-2 Drug induced suicidality 2-4 Pediatric medication errors 4-5 P & T formulary update 5 Risk of myocardial infarction and antiretroviral
More informationA Data Mining Approach for Signal Detection and Analysis
SHORT COMMUNICATION Drug Safety 2002; 25 (6): 393-397 0114-5916/02/0006-0393/$25.00/0 Adis International Limited. All rights reserved. A Data Mining Approach for Signal Detection and Analysis Andrew Bate,
More informationTechnical Guidance Note for Global Fund HIV Proposals
Technical Guidance Note for Global Fund HIV Proposals UNAIDS I World Health Organization I August 2011 Rationale for including pharmacovigilance in the proposal Pharmacovigilance is the science and activities
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationPharmacovigilance Methods and Post-Authorisation Safety Studies
Pharmacovigilance Methods and Post-Authorisation Safety Studies Alex Dodoo Director, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance Accra, Ghana Objectives At the end of this module
More informationNational Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic
National Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioids and Mental Health Policy @HHS_ASH
More informationTN Opioid Program. Erica Schlesinger, Pharm.D
TN Opioid Program Erica Schlesinger, Pharm.D Nothing to disclose Disclosures TN Together Governor Haslam s Plan Prevention Establishes limits, decreases supply and dosage of prescription opioids Limits
More informationOpioid Overview Admiral Brett P. Giroir, M.D.
A S S I S TA N T S E C R E TA RY F O R H E A LT H Opioid Overview Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioid Policy @HHS_ASH August 20, 2018 SUBSTANCE ABUSE
More informationReducing the risk of patient harm: A focus on opioids
Reducing the risk of patient harm: A focus on opioids New York State Partnership for Patients (NYSPFP) Initiative Regional Educational Session November 2013 1 Disclosure Matthew Fricker, Matthew Grissinger,
More informationDrugs Regulatory Unit Ministry of Health PHARMACOVIGILANCE GUIDELINES
Drugs Regulatory Unit Ministry of Health PHARMACOVIGILANCE GUIDELINES THIRD EDITION 2017 0 CONTENTS Introduction 2 Definition and Terminologies..3 Rationale of ADR Monitoring.4 Pharmacovigilance...4 Reporting
More informationIt Takes A Village to Curb the Prescription Opioid Epidemic: Supply healthcare providers with resources to improve patient safety
Session L6 This presenter has nothing to disclose It Takes A Village to Curb the Prescription Opioid Epidemic: CDC Efforts Jan Losby, PhD Team Lead, Overdose Prevention Health Systems Team Division of
More informationFollow this and additional works at:
Regis University epublications at Regis University Celebration of Scholarship and Research Center for Scholarship and Research Engagement Spring -11-17 Implementation of education with ongoing feedback
More informationUse of Secondary Population- Based Databases to Evaluate the Safety of Medications
Methods Report Use of Secondary Population- Based Databases to Evaluate the Safety of Medications Patricia Tennis, Elizabeth Andrews, Lee Lanza, and Catherine Johannes September 2008 RTI Press About the
More informationMedication Errors a challenge of pharmacovigilance BfArM experience
Medication Errors a challenge of pharmacovigilance BfArM experience Dr. Claudia Kayser Federal Institute for Drugs and Medical Devices Medication safety / Pharmacovigilance 1 Disclosure Statement X I have
More informationOpioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices
Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices August 25, 2017 Presented by Michael Crooks, PharmD. Medication Safety and Care Coordination Task Lead 8/28/2017
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationComplete the Qsymia Healthcare Provider Training Program in 2 easy steps:
Overview FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia so that healthcare providers can be informed about the increased risk of teratogenicity associated with Qsymia therapy.
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationAdverse Drug Reactions pattern in a tertiary level teaching hospital: A Retrospective Study
Original Article Adverse Drug Reactions pattern in a tertiary level teaching hospital: A Retrospective Study Anita Gupta, Anjleen Kaur, Prashant Shukla*, Hema Chhabra Department of Pharmacology, Government
More informationAutomatic extraction of adverse drug reaction terms from medical free text
Automatic extraction of adverse drug reaction terms from medical free text Ola Caster Uppsala Monitoring Centre WHO Collaborating Centre for International Drug Monitoring ISCB 2009, Prague, Czech Republic
More informationISMP Targeted Medication Safety Best Practices. Christina Michalek, BS, RPh, FASHP
ISMP 2018-2019 Targeted Medication Safety Best Practices Christina Michalek, BS, RPh, FASHP Objectives At the completion of this activity, you will be able to: Describe the most and least implemented Best
More informationScO.S. Academic Detailing for Safer Prescribing
ScO.S. Academic Detailing for Safer Prescribing Sarah Ball, PharmD Research Assistant Professor MUSC College of Medicine September 6, 2017 Megan Pruitt, PharmD SCORxE Clinical Pharmacy Consultant MUSC
More informationReport to: Public Board of Directors Agenda item: 11 Date of Meeting: 25 July Gosport Hospital Report & RUH Assurance
Report to: Public Board of Directors Agenda item: 11 Date of Meeting: 25 July 2018 Title of Report: Status: Board Sponsor: Author: Appendices Gosport Hospital Report & RUH Assurance For Information Dr
More informationAdverse Events Following Immunisation
Adverse Events Following Immunisation (common, uncommon, shockin rare, and how do we know their likely cause?) Kevin Connolly Portiuncula Hospital, Sept. 18, 2017 Definitions Adverse Event (AE).. untoward
More informationCDC s Approach to Addressing the Opioid Overdose Epidemic
CDC s Approach to Addressing the Opioid Overdose Epidemic Sarah Bacon National Center for Injury Prevention and Control Division of Unintentional Injury Prevention June 23, 2016 500,000 drug overdose deaths
More informationPharmacovigilance: Needs and Objectives
Review Article Pharmacovigilance: Needs and Objectives Ankur Rohilla*, Nishant Singh, Vipin Kumar, Mohit Kumar Sharma, Amarjeet Dahiya, Ashok Kushnoor Department of Pharmaceutical Sciences, Shri Gopi Chand
More informationWhat is the most important information I should know about midazolam?
midazolam (oral) Pronunciation: mye DAZ oh lam Brand: Versed What is the most important information I should know about midazolam? Midazolam can slow or stop your breathing, especially if you have recently
More informationADVERSE DRUG REACTION REPORTS IN MALAYSIA: COMPARISON OF CAUSALITY ASSESSMENTS
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 7 17 (2007) ADVERSE DRUG REACTION REPORTS IN MALAYSIA: COMPARISON OF CAUSALITY ASSESSMENTS HOE SEE LEI 1*, AB FATAH AB RAHMAN 1 AND ABIDA HAQ
More informationReducing Intermittent Infusion Syringe Pump Errors via Weight-Based Safety Parameters
Reducing Intermittent Infusion Syringe Pump Errors via Weight-Based Safety Parameters Alison Bloomquist and Laura Seiberlich Abstract Historically, smart infusion pumps with dose error reduction software
More informationLeeds West CCG Paediatric asthma project. January 2015-January 2017
Leeds West CCG Paediatric asthma project. January 2015-January 2017 Aims to raise asthma awareness improve care reduce emergency attendances and unplanned admissions to secondary care for children with
More informationPharmacist s Role In Pain Management. Katrina Lynn, Pharm D PSHP Annual Assembly: October 12, 2017
Pharmacist s Role In Pain Management Katrina Lynn, Pharm D PSHP Annual Assembly: October 12, 2017 1 Presentation Objectives Briefly discuss Geisinger Health System and the use of Pain Management Pharmacists
More informationAnnex III. Amendments to relevant sections of the Product Information
Annex III Amendments to relevant sections of the Product Information Note: These amendments to the relevant sections of the Summary of Product Characteristics and package leaflet are the outcome of the
More informationResponding to The Joint Commission Alert on Safe Use of Opioids in Hospitals
Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals Suzanne A Nesbit, PharmD, CPE Clinical Pharmacy Specialist, Pain Management The Johns Hopkins Hospital Objectives and Disclosures
More informationOntario s Narcotics Strategy
Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action
More informationNew Guidelines for Opioid Prescribing
New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research
More informationAdverse Drug Reactions (ADRs) Outline
Adverse Drug Reactions (ADRs) Outline 1. What are Adverse Drug Reactions (ADRs)? WHAT WHY HOW 2. How important are ADRs and are they preventable? 3. What are the classifications and mechanisms of ADRs?
More informationRegional Breathlessness Audit - Case Note Survey. 1. Introduction. Regional Breathlessness Audit - Case Note Survey. 2.
Regional Breathlessness Audit - Case te Survey 1. Introduction Please complete this form for your case note review. Cases used may be PROSPECTIVE AND/OR RETROSPECTIVE. Please log as many cases as you can.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate)
PACKAGE LEAFLET: INFORMATION FOR THE USER Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate) Read all of this leaflet carefully before you start using this medicine
More informationRecommendations of fourth meeting of the WHO Advisory Committee on Safety of Medicinal Products 26 and 27 February 2007
Recommendations of fourth meeting of the WHO Advisory Committee on Safety of Medicinal Products 26 and 27 February 2007 The WHO Advisory Committee on Safety of Medicinal Products (ACSoMP) held its fourth
More information50 years of pharmacovigilance: unfinished job
50 years of pharmacovigilance: unfinished job Joan-Ramon Laporte The role of pharmacoepidemiology in medicines regulation 108 market withdrawals in F, D & UK, 1961-93 Fulminant hepatitis Liver toxicity
More informationControlled Substances: A survey of tools and resources required by hospital pharmacists
Controlled Substances: A survey of tools and resources required by hospital pharmacists TABLE OF CONTENTS 2018. Canadian Society of Hospital Pharmacists About the survey 1 The Short and Snappy 1 What CSHP
More informationCSS Perspective - Opioid Risk Management
Tufts Health Care Institute Program on Opioid Risk Management Risk Evaluation and Mitigation Strategy for Prescription Opioids: An In-Depth Review of Fundamental Issues CSS Perspective - Opioid Risk Management
More informationActive TB drug-safety management & monitoring
Active TB drug-safety management & monitoring Global TB Programme, WHO, Switzerland 6 August 2015 Pharmacovigilance: definition of science and activities relating to the detection, assessment, understanding
More informationTechnical Review Meeting of Country Experiences in ARV Toxicity Surveillance: Sharing Results and Lessons Learnt, Identifying Solutions
Technical Review Meeting of Country Experiences in ARV Toxicity Surveillance: Sharing Results and Lessons Learnt, Identifying Solutions 7-8 November 2013, Geneva Excellent healthcare locally delivered
More informationPracticality of direct Reporting Of ADRs by Patients
Practicality of direct Reporting Of ADRs by Patients Evaluation using survey of KAPs of patients towards ADRs & ADR reporting Mala Kharkar Suresh Bowalekar Oct. 27-29,2014 3rd International Conference
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationKey Findings from the ISMP Canada Safety Bulletins Drugs: Oversight, Safety and Supply OHA Educational Event November 20, 2015 Toronto, ON
Key Findings from the ISMP Canada Safety Bulletins Drugs: Oversight, Safety and Supply OHA Educational Event November 20, 2015 Toronto, ON David U President & CEO ISMP Canada Ontario Critical Incident
More information2017 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members
2017 Chronic Respiratory Program Evaluation Our mission is to improve the health and quality of life of our members 2017 Chronic Respiratory Program Evaluation Program Title: Chronic Respiratory Program
More informationQuality. Guaranteeing High Quality. Outsourced Pharmacy Services. Disclosure 3/18/2013
Disclosure Outsourced Pharmacy Services By: Eddie Bostic, RPh For: South Carolina Society of Health System Pharmacist Annual Meeting, March 24 th 2013 Charleston, SC The views and opinions expressed in
More informationPrescription Drug Monitoring Programs and Other State-Level Strategies
Prescription Drug Monitoring Programs and Other State-Level Strategies Interventions to Reduce Opioid-Related Harms: Misuse, Abuse, Addiction, and Overdose Tamara M. Haegerich, PhD Acting Associate Director
More informationNew Guidelines for Prescribing Opioids for Chronic Pain
New Guidelines for Prescribing Opioids for Chronic Pain Andrew Lowe, Pharm.D. CAPA Meeting October 6, 2016 THE EPIDEMIC Chronic Pain and Prescription Opioids 11% of Americans experience daily (chronic)
More informationEvaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration
Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Melissa LD Christopher, PharmD National Director Academic Detailing Program Office
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationResults of a one-year, retrospective medication use evaluation. Joseph Ladd, PharmD PGY-1 Pharmacy Resident BHSF Homestead Hospital
Results of a one-year, retrospective medication use evaluation Joseph Ladd, PharmD PGY-1 Pharmacy Resident BHSF Homestead Hospital Briefly review ketamine s history, mechanism of action, and unique properties
More informationEnsuring Safety of Anticoagulation Therapy
Ensuring Safety of Anticoagulation Therapy Abha Agrawal, MD, FACP Chief Medical Officer Kings County Hospital Clinical Associate Dean SUNY Downstate College of Medicine Brooklyn, NY NYACP Webinar April
More informationOpioid Safety Initiative. Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services
Opioid Safety Initiative Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services 1 2 Opioid Safety Initiative (OSI) Overdose Education and Naloxone Distribution (OEND):
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationResearch Pattern of adverse drug reactions reported to the regional Pharmacovigilance center at Nepal Medical College and Teaching Hospital, Kathmandu
Research Pattern of adverse drug reactions reported to the regional Pharmacovigilance center at Nepal Medical College and Teaching Hospital, Kathmandu Durga Bista 1*, Bal Ram Shrestha 2, Prakash Rai 1,
More informationPolypharmacy. Polypharmacy. Suboptimal Prescribing in Older Adults. Kenneth Schmader, MD Professor of Medicine-Geriatrics
Polypharmacy Kenneth Schmader, MD Professor of Medicine-Geriatrics Polypharmacy Definition Causes Consequences Prevention/management Suboptimal Prescribing in Older Adults Overuse Polypharmacy Underuse
More information